Adaptive Biotechnologies
ADPT
248 hedge funds and large institutions have $4.58B invested in Adaptive Biotechnologies in 2021 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 99 increasing their positions, 77 reducing their positions, and 48 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 77
1% less funds holding
Funds holding: 250 → 248 (-2)
2% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 48
1.72% less ownership
Funds ownership: 83.45% → 81.73% (-1.7%)
12% less call options, than puts
Call options by funds: $23M | Put options by funds: $26M
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
32% less capital invested
Capital invested by funds: $6.75B → $4.58B (-$2.17B)
Top Buyers
Top Sellers
ADPT Hedge Fund Activity: Q1 2021 in Review
248 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q1 2021, worth a combined $4.58B — down 32% from $6.75B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of ADPT and 47 opened new positions — a net loss of 1 holder — while 77 trimmed existing stakes and 99 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $199M. The largest seller was Artisan Partners, exiting entirely with an estimated $120M sold.
- 248 institutional investors held Adaptive Biotechnologies (ADPT) as of Q1 2021, down from 250 in Q4 2020.
- Funds reported $4.58B of Adaptive Biotechnologies stock for Q1 2021, down 32% quarter-over-quarter.
- 47 funds opened new Adaptive Biotechnologies positions in Q1 2021 and 48 closed out, a net change of -1 holder.
- The largest Adaptive Biotechnologies buyer in Q1 2021 was T. Rowe Price Associates, an estimated $199M added.
- The largest Adaptive Biotechnologies seller in Q1 2021 was Artisan Partners, an estimated $120M sold.
Based on aggregated 13F filings for Q1 2021.